Why it finally makes sense to vaccinate boys against HPV
1 October 2019, by Christian Yates

From September 2019, boys aged 12 and 13 in the UK are being offered free vaccination against the Human Papillomavirus (HPV) for the first time. HPV causes cervical cancer, and girls and young women have been receiving the vaccine for over ten years. So why is it being rolled out for boys too? And why only now?

One reason for giving the vaccine to boys is that the vast majority of cases of cervical cancer -causing HPV infections are transmitted through sexual intercourse. Men can carry the virus without symptoms and pass it on to their sexual partners.

In July of 2018, a new mathematical study led to a recommendation that all boys in the UK be given the HPV vaccination at the same age as girls.

This is in part because as well as causing cervical cancer, HPV types 16 and 18 contribute to 50% of penile cancers, 80% of anal cancers, 20% of mouth, and 30% of throat cancers. In both the US and the UK, the majority of cancers caused by HPV are not cervical.

This fact came to the fore when the actor Michael Douglas was asked, during his recovery from throat cancer, if he regretted his lifetime of smoking and drinking. The actor candidly replied that he had no regrets about this, because his cancer had been caused by HPV, which he contracted through oral sex.

Warts and verrucas are also caused by different types of HPV, and 80% of people in the UK will be infected with one strain of HPV at some point during their lives.

Unsurprisingly, given this high prevalence, when the first vaccines against HPV were approved in the US in 2006, there was great hope surrounding their potential. Mathematical modeling studies carried out around that time indicated that the most cost effective strategy would be to immunize adolescent girls between the ages of 12 and 13—the likely future sufferers of cervical cancer.

But, as I uncover in my new book The Maths of Life and Death (along with many other surprising occasions where maths has played a crucial, but sometimes unseen, role) the mathematical models didn't capture the whole picture. Most of the analyses did not include an important feature of HPV in their assumptions: that the strains of HPV guarded against by the vaccine can also cause a range of non-cervical diseases in both women and men.

So cervical cancer is an important part of the HPV picture, but it is not, by any means, the whole story. It seemed that the link to other cancers and diseases had been underestimated.
Michael Douglas spoke candidly about HPV. Credit: Shutterstock/lev radin

The rest of the picture

The public, perhaps aware only of HPV's role in cervical cancer, seemed to accept the decision to only vaccinate females. Why would we waste money vaccinating boys if they don't suffer from the headline HPV cancer?

On top of this, mathematical models into the impact of HPV vaccination suggested that by vaccinating a sufficiently high proportion of females, the prevalence of HPV-related diseases in males would also decline.

But imagine the outrage if a vaccination for human immunodeficiency virus (HIV) was given only to women for free, in the hope that men would be protected through women's immunity.

Perhaps the first point that critics would make (aside from the issues of partial vaccination coverage and vaccine inefficiency) would be about the protection of gay men—why should they be left defenceless against one of the most deadly viruses of our time, just because they don't have sex with women?

Exactly the same argument holds true in the case of HPV. Early mathematical studies had ignored the impact of same sex couplings on the dynamics of HPV spread.

Models that include homosexual relationships suggest a higher rate of sexual disease transmission than those which consider only heterosexual relationships. And the prevalence prevalence of HPV in men who have sex with men is significantly higher than in the general population.

When models were recalibrated to take into account homosexual relationships, protection afforded against non-cervical cancers, and new information on the length of protection that the HPV vaccination provides, it was found that vaccinating boys as well as girls became a more cost-effective option.

Now that the vaccination is finally here, available to boys as well as girls—in a move which will reduce the rates of many kinds of cancer as well as other HPV-related diseases.

This is good news for all of us. And on a personal note I am delighted that my son, as well as my daughter, will now be afforded equal protection against catching and spreading the virus that killed their grandmother. In the case of cervical cancer, as with many of the other cases I have investigated, maths really can be a matter of life and death.

This article is republished from The Conversation under a Creative Commons license. Read the